ACTRN12620000741987进行中（未招募）未知
An Open Label, Multicenter, Observational Study to Assess the Safety, Tolerability and Efficacy of a Pharmaceutical grade Cannabis Medicine (MediCabilis™-CBD extract Oil) in Patients undergoing Medicinal Cannabis Therapy for Different Indications
Bod Australia0 个研究点目标入组 479 人开始时间: 2020年7月16日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 479
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants will be any patient who has been prescribed MediCabilis through the Special Access Scheme B or by an authorised prescriber.
- •Participants may be taking MediCabilis in any dose, form, duration and free
- •quency, and for any condition.
- •Patients of any gender who is equal or greater than 18 years may participate.
- •Prospective patients that understand the informed consent process and to give informed consent to participate in the study.
- •Diagnosis of their condition/disease confirmed by patient’s GP or specialist.
- •Prospective participants agree to abstain from using illicit cannabis products for the duration of their participation in the study.
排除标准
- •Any severe cognitive, intellectual disability, medical or psychiatric condition that impairs the participant’s ability to provide informed consent.
- •Patients who are using illicit forms of cannabis.
研究者
相似试验
招募中
4 期
To find the effectiveness and safety of nefopam tablet in pain associated with trauma.CTRI/2019/06/019801Abbott India Ltd
已完成
4 期
A observational study to evaluate the efficacy and safety of Ranibizumab in patients with visual impairment due to Diabetic Macular Edema(DMECTRI/2015/06/005945ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Open-label study to evaluate the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream in adolescents with severe primary axillary hyperhidrosisSevere primary axillary hyperhidrosisMedDRA version: 20.0Level: PTClassification code 10020642Term: HyperhidrosisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-000922-46-PLDr. August Wolff GmbH & Co. KG Arzneimittel60
进行中（未招募）
1 期
Open-label study to evaluate the safety, local tolerability, systemic exposure, and efficacy of 1% GPB cream in adolescents with severe primary axillary hyperhidrosisEUCTR2022-000922-46-DEDr. August Wolff GmbH & Co. KG Arzneimittel40
已完成
2 期
A study to evaluate the safety and effectiveness of BIOMAB in combination with standard treatments like radio-therapy and drug called Temozolamide in patients with brain tumorCTRI/2013/10/004076Biocon limited56